An Update to Returning Genetic Research Results to Individuals: Perspectives of the Industry Pharmacogenomics Working Group

The ease with which genotyping technologies generate tremendous amounts of data on research participants has been well chronicled, a feat that continues to become both faster and cheaper to perform. In parallel to these advances come additional ethical considerations and debates, one of which center...

Full description

Saved in:  
Bibliographic Details
Authors: Prucka, Sandra K. (Author) ; Arnold, Lester J. (Author) ; Brandt, John E. (Author) ; Gilardi, Sandra (Author) ; Harty, Lea C. (Author) ; Hong, Feng (Author) ; Malia, Joanne (Author) ; Pulford, David J. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: Wiley-Blackwell [2015]
In: Bioethics
Year: 2015, Volume: 29, Issue: 2, Pages: 82-90
IxTheo Classification:NCH Medical ethics
NCJ Ethics of science
Further subjects:B return of results
B pharmacogenomics
B IPWG
B incidental findings
B Pharmaceutical Industry
B Clinical Trials
Online Access: Presumably Free Access
Volltext (Verlag)
Volltext (doi)
Description
Summary:The ease with which genotyping technologies generate tremendous amounts of data on research participants has been well chronicled, a feat that continues to become both faster and cheaper to perform. In parallel to these advances come additional ethical considerations and debates, one of which centers on providing individual research results and incidental findings back to research participants taking part in genetic research efforts. In 2006 the Industry Pharmacogenomics Working Group (I-PWG) offered some ‘Points-to-Consider’ on this topic within the context of the drug development process from those who are affiliated to pharmaceutical companies. Today many of these points remain applicable to the discussion but will be expanded upon in this updated viewpoint from the I-PWG. The exploratory nature of pharmacogenomic work in the pharmaceutical industry is discussed to provide context for why these results typically are not best suited for return. Operational challenges unique to this industry which cause barriers to returning this information are also explained.
ISSN:1467-8519
Contains:Enthalten in: Bioethics
Persistent identifiers:DOI: 10.1111/bioe.12073